The 2023 WHO EGASP study highlights a critical rise in ceftriaxone-resistant gonorrhea in Southeast Asia, with resistance reaching 20% in some regions. These findings underscore the urgent need for enhanced global surveillance and the accelerated development of novel antimicrobial therapies.